Pregabalin (Lyrica) is NOT indicated for brain fog or depression
Pregabalin is FDA-approved only for neuropathic pain conditions, fibromyalgia, and adjunctive seizure treatment—not for depression or cognitive symptoms like brain fog 1. The FDA label explicitly lists approved indications, and neither depression nor brain fog appears among them.
FDA-Approved Indications
According to the official prescribing information, Lyrica is approved for 1:
- Neuropathic pain from diabetic peripheral neuropathy
- Postherpetic neuralgia (shingles pain)
- Fibromyalgia
- Neuropathic pain from spinal cord injury
- Adjunctive therapy for partial-onset seizures
Depression Treatment: Use Evidence-Based Options Instead
For depression, clinicians should select second-generation antidepressants (SSRIs, SNRIs) or cognitive behavioral therapy as first-line treatment 2, 3. The American College of Physicians provides strong recommendations (Grade: strong recommendation, moderate-quality evidence) that when choosing pharmacologic therapy for major depressive disorder, clinicians should select second-generation antidepressants based on adverse effect profiles, cost, and patient preferences 2.
Established antidepressants include 2:
- SSRIs: fluoxetine, sertraline, citalopram, escitalopram, paroxetine
- SNRIs: venlafaxine, duloxetine
- Others: bupropion, mirtazapine
Critical Safety Concerns with Pregabalin
The FDA medication guide warns that pregabalin may cause or worsen depression and suicidal thoughts 1. Specifically:
- Like other antiepileptic drugs, pregabalin may cause suicidal thoughts or actions in approximately 1 in 500 people
- Patients should be monitored for new or worsening depression, anxiety, agitation, or mood changes
- Common adverse effects include dizziness, somnolence, and "thinking abnormal" (primarily difficulty with concentration/attention)—which could exacerbate brain fog 1
Limited Off-Label Evidence
While some small studies suggest pregabalin may help with anxiety symptoms in generalized anxiety disorder 4, 5, 6, the evidence for depression is weak:
- A 2013 retrospective chart review of only 20 patients showed possible benefit when pregabalin was added to antidepressants for residual anxiety in depression 5
- Studies showing benefit were primarily in patients with comorbid anxiety disorders, not depression alone 7, 6
- A 2026 systematic review highlighted severe psychiatric symptoms including psychosis, hallucinations, anxiety, and depression as risks with pregabalin 8
Brain Fog Considerations
Pregabalin commonly causes cognitive impairment, not improvement 1. Clinical trials documented:
- "Thinking abnormal" (difficulty with concentration/attention) in 3-6% of patients
- Confusion in 2-3% of patients
- Amnesia, dizziness, and somnolence as frequent adverse effects
These cognitive side effects would likely worsen, not improve, brain fog symptoms.
Clinical Bottom Line
Do not prescribe pregabalin for brain fog or depression. Instead:
- For depression: Start a second-generation antidepressant (SSRI/SNRI) or refer for cognitive behavioral therapy 2, 3
- For brain fog: Investigate underlying causes (thyroid dysfunction, sleep disorders, medication side effects, depression itself, vitamin deficiencies)
- Assess response: Monitor within 1-2 weeks of starting antidepressant therapy and modify if no adequate response by 6-8 weeks 2
- Continue treatment: Maintain therapy for 4-9 months after satisfactory response for first episode; longer for recurrent depression 2
The risk of worsening cognitive function and mood with pregabalin, combined with lack of FDA approval and minimal supporting evidence, makes it an inappropriate choice for these indications.